{"name":"InventisBio Co., Ltd","slug":"inventisbio-co-ltd","ticker":"","exchange":"","domain":"inventisbio.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"D-2570","genericName":"D-2570","slug":"d-2570","indication":"Metastatic non-small cell lung cancer","status":"phase_3"},{"name":"D-0120","genericName":"D-0120","slug":"d-0120","indication":"Relapsed or refractory chronic lymphocytic leukemia (CLL)","status":"phase_2"},{"name":"D-1553","genericName":"D-1553","slug":"d-1553","indication":"Advanced solid tumors with PI3K pathway alterations","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"D-0502","genericName":"D-0502","slug":"d-0502","indication":"Phase 3 for unspecified indication","status":"phase_3"}]}],"pipeline":[{"name":"D-0502","genericName":"D-0502","slug":"d-0502","phase":"phase_3","mechanism":"D-0502 is a small molecule that targets the molecular target.","indications":["Phase 3 for unspecified indication"],"catalyst":""},{"name":"D-2570","genericName":"D-2570","slug":"d-2570","phase":"phase_3","mechanism":"D-2570 is a small molecule that targets the PI3K/AKT pathway.","indications":["Metastatic non-small cell lung cancer","Metastatic breast cancer"],"catalyst":""},{"name":"D-0120","genericName":"D-0120","slug":"d-0120","phase":"phase_2","mechanism":"D-0120 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Relapsed or refractory chronic lymphocytic leukemia (CLL)"],"catalyst":""},{"name":"D-1553","genericName":"D-1553","slug":"d-1553","phase":"phase_3","mechanism":"D-1553 is a small molecule that targets the PI3K/AKT/mTOR pathway.","indications":["Advanced solid tumors with PI3K pathway alterations"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPQnYxcWVhbVU3T001ZExZZUhydndzQVZsWGxiNnh2V0tuWU5kT0xLbGxQRzktNXQ0RWk2ZTJxYW5PSVhnbVExa1RVY3h1eVd0OU5heHMzSXlyWFVVM0QzMmNfbmh0VXNFTjltNzFwWVRRUFJubDdHU2NsNUxsdGFOMU1fWEhqSnkxSmJzcm4zSTV0UFZNZXZTcXk2RXNYTVljVm9WQlQ3bkNtakdiZGFiQ1lUbjE?oc=5","date":"2026-03-21","type":"pipeline","source":"Markets Mojo","summary":"InventisBio Hits Day Low of CNY 18.27 Amid Price Pressure - Markets Mojo","headline":"InventisBio Hits Day Low of CNY 18.27 Amid Price Pressure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQWHZQeFB1QTBYc3pRRS1tQlNDRjhsQkxhUk4tdWtyaC1XaG1hd2FqaWtJY3VfOURCRlphX2VxSlcyWHhGa2VlWXhUZGZ2SjNIWENyVlNVT01od29nSzJHSmRlTlB0WTB5WndRMDFid0hKNmkwazd4SHdQd2hzSVdJQ25aZGpuT29mOE9yV2I1cWFPU0l0MmJnS0xIMA?oc=5","date":"2026-02-12","type":"pipeline","source":"BioCentury","summary":"Oral SERD field expands — bar for differentiation rises - BioCentury","headline":"Oral SERD field expands — bar for differentiation rises","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOd1p5eUVSN2hiWWtQVTRtdUpxaWExSXZ6OHJfd3U4eFVrWFdxeGtLMlNUa2diSFZBeFZ2bTJQb1U4Z3pVNDQzRldaMUhtSVQ1bHZMY0FabXZaOUhBNFV3bDI1NEdnWC0zaXhuWmRmRXFVMzJIc29hMmlFeU5Pd0QxYzRUWTkzbVE?oc=5","date":"2025-09-19","type":"pipeline","source":"BioWorld News","summary":"Genfleet raises $234M with Hong Kong IPO - BioWorld News","headline":"Genfleet raises $234M with Hong Kong IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPNEx3eVdsSzFHVi1MSUxRenZ3TnlNbHBoSVhmVFBEYnJ3V3FIX1d5TlFFNnRqSnJWZTUxc1A1V3hyQnFIYUxfcXRxMHQ1b2x4bHpNWVRGTjNwci1SQ2FLZlVpQUowdHptTkVIQnpqdTNVWk95ck45aUdfRlBYdUo1d1ozQWxEajB5RGxoTWxnNkl5Y0VGZlBYYXMzeERSR1JVZ1B3dkVOREk2TXVNWWxMTFc4RW9iWkNwVWVIYWVrY0VCX2htU3NreHFGS3NvVFRBTk52TnZQTFFYVTlyYW1kaHRteWIyQTl1ZEpMc24yRkstUktTdUg5YzVXdFlVeldVMXFMY1NOZ1o?oc=5","date":"2025-09-16","type":"trial","source":"GlobeNewswire","summary":"Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight - GlobeNewswire","headline":"Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPZWFwMUJ2dzZvRUlFLUI3blNkbTFtWWoxRmFnNjRyellTdUZ5S1hNVm8yTXcyWDRHeXYyekdPSDZGdUFpVEcxcmdsMW0yX2VwbGMydGJWdFN6WDgwMDFGckFRdHdyTG1qRGwtSkQxangyOElYenFWZV9SNjk4aTlZejk0MmQ?oc=5","date":"2025-04-28","type":"pipeline","source":"Insightace Analytic","summary":"SERD Therapeutics Market Share, Size, Growth and Forecast to 2034 - Insightace Analytic","headline":"SERD Therapeutics Market Share, Size, Growth and Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQOG5sZEpjUzZkYzhvUUl0YVh3QjFuTVdsREQ0SnB0X0trN0NEbmw0Z2ZnZ296dWhQalE1OFNIdHZGYUZ2Q0lIQTQxUElFNWlnbU11dFJWcVQ5Wk12ZWpQaGJyVUZSWnB4NFA0ZXR3TXNIZVNXTFNGb0MtMEl2OC1BaE1NV2xKVnhHM0xJYmpnNVZ5eWUxbDlFczdDaGR3RGV2QlQ0THZkM0RuZ29qZW1kMjcyVGI?oc=5","date":"2024-04-12","type":"pipeline","source":"Seeking Alpha","summary":"Revolution Medicines: An Expensive Shot At A Massive Market Opportunity (NASDAQ:RVMD) - Seeking Alpha","headline":"Revolution Medicines: An Expensive Shot At A Massive Market Opportunity (NASDAQ:RVMD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPSW9hQVI4V2pRVXVLaF9NT2pqWEZ5VmljRGxmWFQ1UkFJSnZ6ZEFpZHp4UmlWNk9lV0ZmZUppeDdSSy1HdzJJa0dOaWpOdkZUb0tXMmxoRjdiSXpsZ1FtVHFSWjZxejAtNVY2S2FQNTdQUTVuaEFneGFJQ1hhTVl1Z2JpOFFEXzl6Zk40T0RVcnVuQQ?oc=5","date":"2020-10-06","type":"pipeline","source":"BioWorld News","summary":"Inventisbio reveals $147M series D funding round - BioWorld News","headline":"Inventisbio reveals $147M series D funding round","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxPeEdVMzUwTHhqSEJ4OE9PTjNTM3cxNzdPcjdUYlROZEd5dVg5VTBxdGMyUzdDYjR6UEhsOWpzVTFSaVBBQTVwN21qR1Z0dUVoSW9xMFppWkxCYlByQVZLanJGZ2RkMGw1S1dzSG9Udm1nX3VjMDJCZElyX20zV2R1MXpKOEdvbndKSTJ0U3RFcjkyem10b2Vnd0hyT05qb3hJM1c0WjQzdGhjVC1kU3NRcDQ1Y09XcnZvbU93a3ZoaVdqTjItTFFOUUw4Tnc0NnZjcmw4WUxMWlF2NnlPM3AtYTItNUhHUjFsU1dtTTVMVXFocVVpd0phZlBWbWFfdw?oc=5","date":"2020-06-22","type":"deal","source":"PR Newswire","summary":"Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China - PR Newswire","headline":"Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":3,"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}